Accumulating evidence suggests that PI3K/Akt/mTOR signaling is involved in the resistance to many cancer therapies, including chemotherapy, RTK inhibitors, anti-angiogenic therapy, mitogen-activated protein kinase (MAPK) pathway inhibitors, hedgehog pathway inhibitors, and immunotherapy [14]. This evidence concerns the gene AKT1 and cancer.